Throughout study | Pre-data collection | Baseline | Program | Follow-up | Program end | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Measures | Nov 25, 2022–Jun 16, 2023 | Nov 25–Dec 23, 2022 | Dec 26, 2022–Jan 23, 2023 | Jan 31–Apr 20, 2023 | Apr 27–Jun 16, 2023 | May 1–May 12, 2023 | ||||||||
− t5a | − t4a | − t3 | − t2 | − t1 | t1 | t2 | t3 | t4 | t5 | t6 | ||||
Eligibility screen | X | |||||||||||||
Informed consent | X | |||||||||||||
Baseline length allocation (3, 4, or 5 weeks) | X | |||||||||||||
Feasibility metrics | X | |||||||||||||
Participant interview | X | |||||||||||||
Instructor interview | X | |||||||||||||
Fidelity monitoring | Xb | Xb | Xb | |||||||||||
Primary definitive trial outcomes | Xa | Xa | X | X | X | X | X | X | X | X | X | |||
Secondary definitive trial outcomes | Xa | Xa | X | X | X | X | X | X | X | X | X | |||
Sociodemographic and medical characteristics | Xa | Xa | Xa | |||||||||||
Adverse events | Xb | Xb | Xb |